Justin B. Klee - Feb 5, 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Feb 5, 2025
Transactions value $
$57,007
Form type
4
Date filed
2/6/2025, 08:17 PM
Previous filing
Feb 5, 2025
Next filing
Mar 5, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $57K +36.3K +1.15% $1.57 3.2M Feb 5, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Options Exercise $0 -36.3K -100% $0.00 0 Feb 5, 2025 Common Stock 36.3K $1.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable.